

IRhythm Pushes a Proactive Approach to Monitoring
“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg I…

Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA
Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Health…

RTW’s Rod Wong on Biotech’s Revival and the Global Shift
“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast…

Cortica’s Plan to Bring Value-Based Care to Autism
“It’s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,” says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is…

Xontogeny's Case for Drug Developers Over Storytellers
“More than half of your time as a public company CEO is devoted to things that are not drug development,” Xontogeny CEO Chris Garabedian says. Garabedian joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain why he earlier left the track …

Roivant’s Playbook for Finding Value Others Miss in Biotech
“In biotech, all of the ideas sound amazing and most of them don’t work.” Roivant CEO Matt Gline joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain how the company tries to tilt those odds through an unconventional model built around f…

Virta Health’s Push to Reverse Metabolic Disease at Scale
“We cannot fix a food problem with drugs,” says Sami Inkinen, CEO and co-founder of Virta Health. Inkinen joins Bloomberg Intelligence analyst Jonathan Palmer to explain why Virta is betting that reversing metabolic disease can become one of the most important cost and outcomes stories in health ca…

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care
“We’re never moving fast enough,” says Bob Segert, CEO of Athenahealth. Segert joins Bloomberg Intelligence analyst Jonathan Palmer to explain the strategic reset that reshaped Athenahealth: cutting losing bets, doubling down on ambulatory care and building around its cloud-native athenaOne platfor…

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough
“This deal [with Eli Lilly, announced on Sunday 29 March] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,” says Alex Zhavoronkov, founder and co-CEO of Insilico Medicin…

Abridge Moving AI From Scribing to Clinical Workflows
“I think 2026 is the year of fundamental, agentic transformation of the workflow.” Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care’s breakout AI leaders. Lipton breaks down t…